Response

Affiliations

¹ Guy's Severe Asthma Centre, Guy's & St Thomas' NHS Trust, and the Asthma UK Centre, King's College London, London, UK.
² Guy's Severe Asthma Centre, Guy's & St Thomas' NHS Trust, and the Asthma UK Centre, King's College London, London, UK. Electronic address: david.jackson@gstt.nhs.uk.

Comment

Joanne E Kavanagh et al. Chest. 2020 Nov.

. 2020 Nov;158(5):2230-2231.

doi: 10.1016/j.chest.2020.06.061.

¹ Guy's Severe Asthma Centre, Guy's & St Thomas' NHS Trust, and the Asthma UK Centre, King's College London, London, UK.
² Guy's Severe Asthma Centre, Guy's & St Thomas' NHS Trust, and the Asthma UK Centre, King's College London, London, UK. Electronic address: david.jackson@gstt.nhs.uk.

No abstract available

Comment on

Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
Kavanagh JE, d'Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, Jackson DJ. Kavanagh JE, et al. Chest. 2020 Aug;158(2):491-500. doi: 10.1016/j.chest.2020.03.042. Epub 2020 Apr 8. Chest. 2020. PMID: 32275980
Careful Selection of Patients Is Required to Obtain Higher Potential Benefit From Mepolizumab Therapy.
Yılmaz İ. Yılmaz İ. Chest. 2020 Nov;158(5):2229-2230. doi: 10.1016/j.chest.2020.05.612. Chest. 2020. PMID: 33160530 No abstract available.